{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3777, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes company logo, date, and a molecular visualization.", "imagePath": "https://imgproxy.kitesheet.com/YoLy0YZH-Ew1M5y_a0bI8zjI8uYmL29QdF_S9CX6eH8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/1", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/w8QTyTVW7HOUW_lcaSXBhrNskddoEOHXSEfzgm59IhY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/RvnTemiagfzMbfr6ivnEuK4omqhP3NLKKrjBLw3I9vc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/IsuRG28LsqhzjOJXgmzTjO5jP2oyHMwvmQ2y-TGfZ7Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLnBuZw" }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/2", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/3", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/4", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a chronological structure to demonstrate operational momentum.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/5", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/6", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "team_bio", "function": "other", "notes": "The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/7", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style visualization to represent drug development stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/8", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-8", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a structured table to highlight gaps in current treatment standards.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/9", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-9", "loopMatches": [ { "to": 11, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 9, "from": 9, "beatId": "7c3004c9-d14e-4ddd-ac8b-469b44ef6e17", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events in current cancer therapies.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "illustrate_case", "notes": "Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/10", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-10", "loopMatches": [ { "to": 11, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 10, "beatId": "27328397-5fb0-424b-acf4-4be675fda1d4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents Nuvalent's solution, including their innovative approach to cancer therapy and promising clinical trial results.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/11", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-11", "loopMatches": [ { "to": 11, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 11, "from": 11, "beatId": "7d7613a4-2fa9-47a2-8dd6-439e4bd4ffa2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": null, "evidence": "The document presents the market sizing for Nuvalent's therapies, highlighting the significant commercial opportunity.", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "solution", "function": "present_solution", "notes": "Slide 12 of the deck.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/12", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-12", "loopMatches": [ { "to": 14, "from": 12, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 12, "from": 12, "beatId": "b1774785-2429-4d83-9f6f-95b57f9114be", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the product details for Nuvalent's therapies, including NVL-655 and NVL-520.", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "customer_journey", "function": "frame_problem", "notes": "The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/13", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-13", "loopMatches": [ { "to": 14, "from": 12, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/14", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-14", "loopMatches": [ { "to": 14, "from": 12, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/15", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-15", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/16", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-16", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes detailed clinical trial enrollment metrics by dose cohort and patient population.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/17", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/18", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-18", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "traction", "function": "analyze_data", "notes": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/19", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-19", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "show_traction", "notes": "Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/20", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/21", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "product_demo", "function": "show_traction", "notes": "Includes two patient case studies with MRI scans showing tumor reduction.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/22", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data cut-off: 8 Aug 2023. N=93 patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/23", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/24", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide outlines a multi-cohort study design with specific patient populations and trial objectives.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/25", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "context", "function": "establish_context", "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key drug development parameters.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/26", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "customer_journey", "function": "present_framework", "notes": "The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/27", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/28", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "solution", "function": "present_solution", "notes": "The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/29", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "traction", "function": "show_traction", "notes": "The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/30", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/31", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "traction", "function": "show_traction", "notes": "Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/32", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "Includes clinical trial data from ARROS-1 Phase 1 study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/33", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data as of 13 Sep 2022. N=35 patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/34", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/35", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/36", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/37", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "product_demo", "function": "present_solution", "notes": "The slide uses a 'Target Product Profile' framework to summarize the drug's key characteristics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/38", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "solution", "function": "present_solution", "notes": "Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/39", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "timeline", "function": "plan_implementation", "notes": "The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/40", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "docSlug": "5062b9a9257606648ea145bccd66e04d", "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/41", "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "Includes a summary table of ORR and best response, and a waterfall plot showing individual patient tumor regression.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/33", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "show_traction", "notes": "Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/34", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "analyze_data", "notes": "Data as of 13 Sep 2022. N=35 patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/35", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "traction", "function": "show_traction", "notes": "The chart shows pharmacokinetic data (NVL-520 concentration over time) compared against target efficacy thresholds for different ROS1 variants.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/36", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "why_now", "function": "argue_timing", "notes": "Uses a side-by-side comparison framework to contrast 2L+ (salvage) and 1L (front-line) market opportunities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/37", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/38", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a 'ribbon' style callout box on the right for key product attributes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/39", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "product_demo", "function": "present_solution", "notes": "The slide uses three distinct chart types to demonstrate superiority in three key pharmacological areas.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/40", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a timeline framework to connect current clinical progress to a 2026 goal of product approval.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/41", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b731-71da-a78f-007719e300bb", "docSlug": "1616e8b22ac58e7f024f1153201d610f", "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/42", "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb", "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-42", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/kUTR5rJhNDzZVXaIu0pXuS9s0tDTJQkjlXLzy57j88Q/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ODU2NDlkNmFkM2JmMWY4N2JkMjY0MTMyYmVkNDRjMS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/1", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/h5B3ELUx01iqcE-8Xt45gTxi1uRJP42Ci7mrgpNiX7w/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ODU2NDlkNmFkM2JmMWY4N2JkMjY0MTMyYmVkNDRjMS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/5L5BDzK5dGwZEPdBaalJJ6kcCy6crjj4k7X4oNRl__A/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ODU2NDlkNmFkM2JmMWY4N2JkMjY0MTMyYmVkNDRjMS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/xnlby1EoYJO-_6T3IozT3lHQCu6J-UjH9BBi4fQWItI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83ODU2NDlkNmFkM2JmMWY4N2JkMjY0MTMyYmVkNDRjMS9wMDAxLnBuZw" }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/2", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/3", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-3", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a visual layout to associate each executive with specific past pharmaceutical successes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/4", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-4", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/5", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-5", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/6", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-6", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 6, "from": 6, "beatId": "03e2260f-d33c-4664-978b-0ce6754896b9", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Introduction to NXP800", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "solution", "function": "present_solution", "notes": "Includes a biological pathway diagram and a dose-response curve showing target validation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/7", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-7", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 9, "from": 7, "beatId": "816636d5-21da-498e-b716-dab6ea2ab36b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Mechanism of Action and clinical results for NXP800", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/8", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-8", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 9, "from": 7, "beatId": "816636d5-21da-498e-b716-dab6ea2ab36b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Mechanism of Action and clinical results for NXP800", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-b8a1-76db-a88b-3941d3b29d31", "docSlug": "785649d6ad3bf1f87bd264132bed44c1", "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides", "authorId": "nuvectis-pharma", "authorName": "Nuvectis Pharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "traction", "function": "show_traction", "notes": "Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/9", "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31", "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-9", "loopMatches": [ { "to": 13, "from": 3, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431", "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts", "position": 0, "objective": "Highlight the need for new cancer treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 9, "from": 7, "beatId": "816636d5-21da-498e-b716-dab6ea2ab36b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Mechanism of Action and clinical results for NXP800", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 13, "from": 9, "beatId": "e517dce6-8161-47a1-8122-29fab4f84ad6", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and Phase 1b update for NXP800", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }